Zoetis (NYSE:ZTS) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus estimate of $3.05. The company issued revenue guidance of $5.7-5.8 billion, compared to the consensus revenue estimate of $5.74 billion.
Several research analysts have recently weighed in on the company. Cantor Fitzgerald set a $98.00 target price on Zoetis and gave the stock a buy rating in a report on Thursday. Bank of America boosted their target price on Zoetis from $97.00 to $100.00 and gave the stock a buy rating in a report on Monday. Jefferies Financial Group set a $96.00 target price on Zoetis and gave the stock a buy rating in a report on Friday, July 13th. BMO Capital Markets restated a hold rating and set a $80.00 target price on shares of Zoetis in a report on Wednesday, May 16th. Finally, Craig Hallum reiterated a buy rating and issued a $94.00 price objective (up from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $85.60.
Get Zoetis alerts:Zoetis traded up $2.44, reaching $88.46, during trading hours on Thursday, according to Marketbeat Ratings. The company’s stock had a trading volume of 158,219 shares, compared to its average volume of 2,386,192. Zoetis has a fifty-two week low of $59.50 and a fifty-two week high of $89.25. The stock has a market capitalization of $41.84 billion, a PE ratio of 36.86, a P/E/G ratio of 1.78 and a beta of 1.02. The company has a debt-to-equity ratio of 2.51, a quick ratio of 2.83 and a current ratio of 4.27.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.70 by $0.07. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The firm had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.38 billion. During the same period in the prior year, the firm posted $0.53 earnings per share. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. equities research analysts forecast that Zoetis will post 3.05 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s dividend payout ratio is presently 20.83%.
In other Zoetis news, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $84.76, for a total value of $169,520.00. Following the sale, the insider now owns 22,023 shares of the company’s stock, valued at $1,866,669.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.
About Zoetis
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What does EPS mean?
